Evidence map›Paper›PMID 29084453›Full record

ArticleThe American journal of psychiatry2017

Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice.

Iva Dincheva, Jianmin Yang, Anfei Li, Tina Marinic, Helena Freilingsdorf, Chienchun Huang, B J Casey, Barbara Hempstead, Charles E Glatt, Francis S Lee and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. BDNF: New Views of an Old Player in Traumatic Brain Injury.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024
    Review
  5. Depression in Adolescence and Brain-Derived Neurotrophic Factor.Frontiers in molecular neuroscience · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Critical Issues inFrontiers in molecular neuroscience · 2018
    Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Iva DinchevaFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Jianmin YangFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Anfei LiFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Tina MarinicFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Helena FreilingsdorfFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Chienchun HuangFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
B J CaseyFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Barbara HempsteadFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Charles E GlattFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Francis S LeeFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Kevin G BathFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Deqiang JingFrom the Departments of Psychiatry, Pharmacology, and Medicine and the Sackler Institute for Developmental Psychobiology, Weill Cornell Medical College, Cornell University, New York; the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China; the Department of Psychology, Yale University, New Haven, Conn.; and the Department of Psychology, Brown University, Providence, R.I.
Cornell University · US

Funding

Training CoreP20GM103430 · NIGMS · UNIVERSITY OF RHODE ISLAND · PI Bongsup P Cho · 2012 to 2026
$63.6M
Statistical Genetics Core: Impact of BDNF Genotype and Stress on LearningP50MH079513 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI CASEY, BETTY J · 2008 to 2012
$9.4M
The Impact of the BDNF Val66Met Prodomain on Cognitive Function in a Mouse Model of Alzheimer's DiseaseR01NS052819 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HEMPSTEAD, BARBARA L, LEE, FRANCIS SANG YONG · 2005 to 2019
$5.3M
NIGMS NIH HHS P20 GM103430NIMH NIH HHS P50 MH079513NINDS NIH HHS R01 NS052819
6 · The paper itself

Abstract

objectiveAdolescence is a developmental stage in which the incidence of psychiatric disorders, such as anxiety disorders, peaks. Selective serotonin reuptake inhibitors (SSRIs) are the main class of agents used to treat anxiety disorders. However, the impact of SSRIs on the developing brain during adolescence remains unknown. The authors assessed the impact of developmentally timed SSRI administration in a genetic mouse model displaying elevated anxiety-like behaviors.

methodKnock-in mice containing a common human single-nucleotide polymorphism (Val66Met; rs6265) in brain-derived neurotrophic factor (BDNF), a growth factor implicated in the mechanism of action of SSRIs, were studied based on their established phenotype of increased anxiety-like behavior. Timed administration of fluoxetine was delivered during one of three developmental periods (postnatal days 21-42, 40-61, or 60-81), spanning the transition from childhood to adulthood. Neurochemical and anxiety-like behavioral analyses were performed.

resultsWe identified a "sensitive period" during periadolescence (postnatal days 21-42) in which developmentally timed fluoxetine administration rescued anxiety-like phenotypes in BDNF Val66Met mice in adulthood. Compared with littermate controls, BDNF

conclusionsThese findings suggest that SSRI administration during a "sensitive period" during periadolescence leads to long-lasting anxiolytic effects in a genetic mouse model of elevated anxiety-like behaviors. These persistent effects highlight the role of BDNF in the maturation of the serotonin system and the capacity to enhance its development through a pharmacological intervention.

Indexed as

Age FactorsAnimalsAnti-Anxiety AgentsAnxietyBrain-Derived Neurotrophic FactorDorsal Raphe NucleusEatingFearFluoxetineGene Knock-In TechniquesMaleMaze LearningMicePolymorphism, Single NucleotidePrefrontal CortexS100 Calcium Binding Protein beta SubunitAnti-Anxiety AgentsBrain-Derived Neurotrophic FactorFluoxetineS100b protein, mouseS100 Calcium Binding Protein beta SubunitSelective Serotonin Reuptake InhibitorsAntidepressantsAnxiety Disorder-GeneralizedBDNFDevelopment

Identifiers

PMID29084453
PMCPMC5711544
OpenAlexW2766002229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.